Vanderbilt Center for Antibody Therapeutics (VCAT)
-
February 6, 2020
Antibody mixture may help block Ebola virus infection
A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus. -
February 6, 2020
Carnahan named associate director of Vaccine Center
Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center. -
January 23, 2020
Antibody isolated at VUMC found to halt dengue virus
Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection. -
December 12, 2019
VUMC-led team isolates antibody that blocks bird flu
VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans. -
September 13, 2019
Early effort to thwart chikungunya infection shows positive results
Phase 1 trial results in new approach to combat the chikungunya -
September 4, 2019
Partnership to help bring Zika virus therapy to clinic
Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. -
August 29, 2019
Exceptional graduate students honored with Dean’s Award
Eleven graduate students entering their fourth year of training have received the Dean’s Award for Exceptional Achievement in Graduate Studies.